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To the Editor:
Chimeric antigen receptors (CARs) have undoubtedly
revolutionized immunotherapy, especially in the B-cell
acute lymphoblastic leukemia (ALL) arena where over 80%
of complete remissions are observed in refractory/relapsed
(R/R) B-cell ALL patients treated with CD19-directed CAR
T-cells (CARTs) [1]. However, despite holding an unpre-
cedented promise, several issues still have to be resolved
before CARTs can be expanded to novel targets and/or
malignancies or even provided as first-line treatment in B-
cell ALL [2]. For instance, toxicities such as cytokine
release syndrome and immune escape mechanisms includ-
ing loss of the antigen under CART-mediated pressure
remain major concerns, urging further research on the
mechanisms underlying CARTs cytotoxicity.
In this sense, loss of CD19 antigen is frequently observed
after CD19-directed CARTs therapy in B-cell ALL [3, 4],
but is particularly common in MLL-rearranged (MLLr) B-
cell ALL, an aggressive subtype of B-cell ALL (dismal in
MLL-AF4+ infants) associated with lymphoid-to-myeloid
lineage switch [3, 5, 6]. We read with interest the work
recently published in Leukemia by Li et al. reporting a
novel CAR targeting both CD19 and CD133 [7]. This study
proposes to use a bi-specific CAR targeting both CD19 and
CD133 antigens in a Boolean OR-gate approach for MLLr
B-cell ALL as a strategy to avoid and treat CD19- relapses.
The authors reasoned that CD133, encoded by PROM1
gene, is a specific marker for MLLr leukemia because
PROM1 is an MLL target, especially in MLL-AF4 B-cell
ALL [8–10]. They went on and performed in vitro assays
showing than CD19/CD133 bi-specific CAR triggers robust
cytotoxicity against CD19+ CD133+ and CD19-CD133+
B-cell lines [7], thus suggesting it may help in reducing
subsequent lineage switch in MLLr B-cell ALL.
A major drawback for CD133 as target in immu-
notherapy is its expression in hematopoietic stem and
progenitor cells (HSPCs), which would likely exert “on-
target off-tumor” myeloablative, life-threatening toxicity
[11, 12]. Because B-cell ALL is molecularly hetero-
geneous and can be diagnosed during infancy, childhood
and adulthood, we have characterized PROM1/CD133
expression in a large cohort of cytogenetically distinct B-
cell ALL subgroups (n= 212 patients) as well as in dif-
ferent subpopulations of normal CD34+ HSPCs obtained
across hematopoietic ontogeny from 22-weeks old human
fetal liver (FL, prenatal), cord blood (CB, perinatal), and
adult G-CSF-mobilized peripheral blood/bone marrow
(PB/BM, postnatal). An initial analysis of publicly
available RNA-seq data [13] from 170 diagnostic B-cell
ALL patients confirmed that PROM1 is overexpressed in
patients with MLLr B-cell ALL, although its expression is
not significantly higher than in other cytogenetic sub-
groups (Fig. 1a). We then analyzed PROM1 during HSPC
development and observed that PROM1 is highly
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and multipotent progenitors (MPP) with its expression
decreasing from the lymphoid-primed multipotent pro-
genitors (LMPP) onwards with its expression being mar-
ginal at later stages of myeloid differentiation
(megakaryocyte-erythroid progenitors, MEP) and com-
mon lymphoid progenitors (CLP) [14] (Fig. 1b). Impor-
tantly, 70% (22/32) of 11q23/MLLr B-cell patients (both
MLL-AF4 and MLL-AF9) express equal (9/32) or lower
(13/32) PROM1 levels that HSCs and MPPs, which raises
doubts about the suitability of PROM1 as a target for B-
cell ALL immunotherapy [15].
FACS clinical immunophenotyping provides a priori a
more rapid and feasible clinically relevant diagnostic
information than RNA-seq during the decision-making
process. Thus, we next FACS-analyzed the expression of































































































































Prenatal CD34  Cells (FL/BM-derived cells) n=8
Perinatal CD34  Cells (CB-derived cells) n=7
Postnatal CD34  Cells (BM/PB-derived cells) n=7
MLL germline B-ALL n=5 (3 Relapses, 2 PDX)
11q23/MLLr B-ALL n=7 (3 Diagnostics, 4 PDX)
Fig. 1 Characterization of CD133/PROM1 expression in B-cell ALL
and normal HSPCs. a Expression level of PROM1 in the indicated
cytogenetic subgroups of B-cell ALL (n= 170 patients at diagnosis)
determined by RNA-seq represented in log2(CPM) scale, with CPM
= counts per million [13]. b RNA-seq analysis comparing the
expression of PROM1 in 11q23/MLLr B-cell ALL (n= 29 patients)
with that in distinct fractions of Lin-CD34+ CD38-CD19- non-
lymphoid normal HSPCs (HSC hematopoietic stem cells, MPP mul-
tipotent progenitors, LMPP lymphoid-primed multipotent progenitors,
CMP common myeloid progenitors, GMP granulocyte-monocyte
progenitor, MEP megakaryocyte-erythroid progenitors) and in
common lymphoid progenitors (CLP) [14]. Data shown as normalized
counts. The boxes define the first and third quartiles. The horizontal
line within the box represents the median. c Frequency (left) and mean
fluorescence intensity (MFI, middle) of CD133+ BM blasts/cells in
MLLr (n= 7) and non-MLL B-cell ALLs (n= 5) primary diagnostic/
relapse samples or primografts (PDXs), and normal CD34+ HSPCs
derived from FL (n= 8), CB (n= 7) and adult PB/BM (n= 7).
Representative FACS dot plots for CD133 in normal CD34+ HSPCs
(upper right) and BM samples from two independent MLLr B-cell
ALL patients (bottom right)
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derived primary blasts and primografts (PDXs) obtained
from 11q23/MLLr (n= 7) and non-MLL (n= 5) B-cell
ALL patients, and in comparison with healthy prenatal
(22 weeks old FL), perinatal (CB) and adult (PB/BM) CD34
+ HSPCs (Fig. 1c). Consistent with the RNA-seq data, the
expression of CD133 in 11q23/MLLr blasts is intermingled
with that observed in CD34+ HSPCs across hematopoietic
ontogeny (Fig. 1c).
Our data demonstrates that PROM1/CD133 is similarly
expressed between MLLr B-cell ALL primary blasts and
normal non-lymphoid HSPCs across ontogeny, thus indi-
cating that “on-target, off-tumor” toxic/myeloablative
effects are likely to occur if used in a bi-specific CAR
approach where CD133 antigen will be constantly targeted
regardless of the co-expression of CD19 in the same cell.
Our data therefore raises concerns about using CD133 as a
target for MLLr B-cell ALL immunotherapy. An alternative
to circumvent HSPC toxicity would be to engineer dual
CAR T-cells with one CAR engaging an antigen (i.e.,
CD19) mediating T-cell activation and another CAR
engaging a second antigen (i.e., CD133) mediating T-cell
co-stimulation [16]. Unfortunately, although such a CD19/
CD133 dual CAR might be likely safe due to its cytotoxi-
city being restrained only to cells co-expressing CD19 and
CD133, its specific cytotoxic performance will be poor
since not the entire MLLr B-cell ALL blast population is
CD19+CD133+ (Fig. 1c). Another alternative approach to
prevent HSPC toxicity would be to have in place a potent
molecular switch (i.e., iCas9) to eliminate CAR133-
expressing T-cells as necessary [17]. Further long-term
in vivo studies using both primary B-cell ALL cells and
normal HSCPs remain to be conducted to elucidate the
efficacy versus the myeloablative toxicity of a CAR CD133
[18, 19].
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To the Editor:
Short-dysfunctional telomeres are detected prior to clinical
progression in chronic lymphocytic leukaemia (CLL) and
result in chromosomal fusions that propagate genome
instability, driving disease progression. To investigate the
impact of telomere dysfunction on the CLL genome, we
performed a large-scale molecular characterisation of telo-
mere fusion events in CLL B-cells. A cohort of 276 CLL
patient samples was selected for analysis based on short
telomere length (TL) profiles, with the majority (97%, n=
269) having mean TL within the previously-defined fuso-
genic range in CLL [1]. Patient samples were screened for
the presence of telomere fusions using a single-molecule
telomere fusion assay [2] modified to include the 5p telo-
mere (Supplementary Figure 1). Telomere fusions were
detected in 72% (198/276) of the samples, which were
subsequently arbitrarily stratified by fusion frequency
(Supplementary Table 1). Fusions were detected for all
telomeres assayed, including the 5p telomere, for which
fusions were present in 23% (40/177) of patient samples
(Supplementary Figure 2, Supplementary Table 2).
High-resolution characterisation of single-molecule
amplified telomere fusions from nine CLL patients with
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the highest fusion frequency was performed by Illumina
HiSeq4000 paired-end sequencing. Following a customised
bioinformatics analysis pipeline [3] and manual curation
(Supplementary Figure 3), 914 unique telomere fusions were
resolved (Supplementary Figure 4), of which 19% (172/914)
involved the 5p telomere (Supplementary Figure 5). Intra-
(sister-chromatid) or inter-chromosomal telomere fusion
events were identified, as well as recombinations involving
non-telomeric loci incorporated into telomere fusions
(Fig. 1; Supplementary Figure 4, Supplementary Table 3).
These captured loci included; the ancestral telomere at
Chr2q13-14 (n= 11), mitochondrial DNA (n= 4) and
other non-telomeric genomic loci (n= 78). Complex inter-
chromosomal events involving multiple disparate loci were
also detected (n= 7) (Supplementary Figures 5–9).
Distinct signatures of telomere fusions across the gen-
ome could be described for each CLL patient sample
(Fig. 1). Two patients (CLL3 and CLL6) displayed sim-
ple signatures, defined by the presence solely of intra-
chromosomal and/or inter-chromosomal telomere-telomere
Fig. 1 Signature of telomere fusions for 9 CLL patient samples.
Circos plots showing the validated results obtained from the inter-
chromosomal and intra-chromosomal telomere fusion analysis from
nine CLL patient samples. Circos plot with each chromosome and
its telomeres (1p telomere, Chr1, 1q telomere) around the circle
orientated clockwise. Additional notches indicate linkages specifi-
cally aligning with subtelomeric sequence references derived from
Stong et al. [12]. Colour code: telomere-telomere inter-chromosomal
(black), telomere-telomere intra-chromosomal for 5p, 17p and XpYp
(blue), inter-chromosomal or intra-chromosomal for 16p and 21q
families (light blue), and inter-chromosomal telomere-genomic
(green), telomere-2q13 (orange) and telomere-ChrM (pink). Telo-
mere fusion events with unknown sub-telomeric sequence were not
included
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fusions. In contrast, the CLL8 sample telomere fusion
profile revealed abundant genomic linkages, including with
the ancestral telomere at 2q13 and mitochondrial DNA.
Samples CLL1, CLL2, CLL4, CLL5, CLL7 and CLL9 were
characterised by complex signatures with a combination of
most or all categories of telomere fusion events identified in
this study (Fig. 1; Supplementary Table 4).
Telomere dysfunction is associated with increased
genomic instability and disease progression in CLL [1, 4],
therefore a comprehensive analysis of all patient-derived
telomere fusions with non-telomeric genomic loci was
undertaken. Locations and junction sequences pertaining to
all 93 (10% total fusions) identified inter-chromosomal
fusions were investigated to determine commonality of
global or local sequence context as well as providing evi-
dence for the engagement of specific DNA repair processes.
These inter-chromosomal genomic fusions were less abun-
dant than pure telomeric inter-chromosomal fusions that
represented 38% of all fusions characterised.
Inter-chromosomal fusions with non-telomeric genomic
loci were identified in all nine CLL patient samples. Indi-
vidual events were validated by manual sequence analysis,
revealing 68% (63/93) had fusion junctions covered by
junction-spanning sequence read pairs (mFJ) and 32%
(30/93) had unmapped junctions (uFJ). Each fusion junction
location was depicted on the ideogram in Fig. 2a. Notably,
the loci disrupted by telomere fusions (summarised in
Supplementary Table 5) were not randomly distributed
throughout the genome since there was no simple correla-
tion with chromosome length (r2= 0.44) or coding gene
density of the respective chromosomes (r2= 0.32) (Fig. 2b,
Supplementary Figure 10). However, loci with previously-
reported copy number aberrations in CLL [5] were found to
be incorporated into telomere fusions, including 2p15,
2p11.2 (2 events), 2q13 (11 events), 6q22.31, 11q22.2 and
18q21.32 (single events). In addition, a complex telomere
fusion was detected involving four distinct loci including
13q14.2 that is frequently deleted in CLL (Supplementary
Figure 4B).
Inter-chromosomal telomere fusions occurred within cod-
ing DNA more frequently than expected by chance. Over half
(57%) of mFJ were within introns and exons of protein-
coding genes (Supplementary Table 5), significantly higher
(Chi-squared analysis p= 0.0024) than the average 42% gene
content of the human genome (based on the hg19 RefGene).
We also observed 15% and 9% mFJ fused with Common
Fragile Sites (CFSs) and Alu elements, respectively; however,
these were similar to the proportion of CFSs (15%) and Alu
sequences (11%) identified across the human genome [6].
All 31 protein-coding genes disrupted by telomere
fusions with mFJ were further investigated for potential
association with CLL pathogenesis (Supplementary Table 6).
An enrichment in genes overexpressed in CD38+ patient
CLL B-cells was revealed using GSEA Gene Set Enrichment
Analysis (GSEA, v5.2) Molecular Signatures Database
(MSigDB) [7]. This gene set included HTR7, KIF26B and
LPHN1 (p-value 1.5e−6; FDR q-value 2.7e−2) —genes pre-
viously found to be upregulated in CD5+/CD19+/CD38+
CLL cells associated with worse patient prognosis, compared
with patient-matched CD5−/CD19−/CD38− CLL cells in a
panel of six patient samples [8]. Strikingly, 36% (11/31) of
all genes disrupted by a telomere fusion event for which the
junction could be validated were classified as expressed or
associated with B lymphocytes or CLL B-cells. These genes
included CD8A, RORA, TESPA1, DMD, NOX5, NTF3, EVI5
and FTO (Supplementary Table 7) with documented patho-
logical relevance. A significant enrichment in genes posses-
sing binding motifs matching the B-cell-expressed homeobox
transcription factor, HNF1α (TCF1) [9], within their pro-
moters was also identified (DMD, RORA, NTF3 and HTR7;
p-value 2.51e−5; FDR q-value 1.31e−2; Supplementary
Table 8). Furthermore, a noteworthy association of fusion-
disrupted genes with gene sets over-expressed in other types
of cancer including breast and liver was also revealed by
these analyses.
We have previously shown that intra-chromosomal telo-
mere fusion is accompanied by extensive resection that results
in asymmetric deletion of the participating sister-chromatids
[3]. To assess whether this was true for CLL B-cells, the extent
of DNA end-processing at each sister-chromatid was exam-
ined for intra-chromosomal fusions with mFJ. The distance
from the start of the telomere repeat sequences to the fusion
junction for each of the chromatids involved in the fusion
event was determined and the difference calculated to obtain a
measure of asymmetry (Fig. 2c, d; Supplementary Tables 9-
10). The uneven distribution of fusion junctions across the 5p
sub-telomere (n= 14) is consistent with the location of a CpG
island and suggests that the GC-rich sequence may hamper the
detection of 5p fusion events (Supplementary Figure 11).
Thus, 5p telomere fusions may be under-represented in the
data and may have an even greater impact on CLL disease
than presently recognised. In contrast, telomere fusion junc-
tions were effectively captured across the 17p (n= 30) and
XpYp (n= 20) telomeres (Fig. 2c). Asymmetry of sister-
chromatids was observed for 5p, 17p and XpYp with a mean
of 1408 bp, 1240 bp and 695 bp, respectively (Fig. 2d). The
degree of asymmetry was significantly greater than the theo-
retical value 0 (one sample t-test, p < 0.001). This indicates
that fusion occurs between sister-chromatids of different
lengths in CLL B-cells, consistent with our observations in
other models [2, 3, 10]. No significant differences were found
in the extent of asymmetry between the 5p, 17p and XpYp
chromosome ends (Kruskal-Wallis, p= 0.1661).
High-resolution analysis of each CLL mFJ was per-
formed to investigate candidate DNA repair mechanisms
that may underlie distinct types of telomere fusion events.
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Insertions of templated, untemplated and/or potential telo-
mere variant repeat sequences were observed at 6%
(50/796) of mFJ: 23/50 for Telomere-Sub-telomere, 4/50
for intra-chromosomal, 2/50 for intra/inter, 19/50 for telo-
meric inter-chromosomal, 1/50 for telomere-Chr2q13 and
1/50 for telomere-ChrM fusions. Insertions ranged from
1-21 nucleotides with a mean of 4.5 nucleotides. In contrast,
no insertions were identified at fusions with non-telomeric
loci. Statistically-significant differences in the extent of
microhomology usage at fusion junctions were determined
for the different types of telomere fusion events (Kruskal-
Wallis p < 0.001 and Dunn’s Multiple Comparison Test)
Fig. 2 Characterisation of telomere fusions detected across the gen-
ome. a Validated inter-chromosomal telomere fusion events (n= 93)
on a karyotype map generated in Ensembl. Telomere fusions with
genomic, ancestral telomere 2q13 and mitochondria DNA/Chr. Each
colour represents a different patient sample. Continuous arrow-heads
indicate mapped fusion junctions (mFJ) and discontinuous arrow-
heads represent unmapped fusion junctions (uFJ, location of the read
represented). b Number of validated inter-chromosomal telomere-
genomic fusion junctions per Mb of DNA for each chromosome
ordered by length (size obtained from Ensembl). c Sister-chromatid
deletion and d asymmetry for the 5p, 17p and Xp chromosome ends of
intra-chromosomal fusion events. Green box highlights the CpG island
on the 5p sub-telomere. Location of the fusion primer indicated,
determines the limit of the assay from the telomere. d Level of
asymmetry was determined by calculating the deletion difference
between each chromatid of the same fusion event. e Microhomology
(bp) at the fusion junction was compared for the distinct type of
events: TTAGGG-CCCTAA (00), Sub-telomere-TTAGGG (0), intra-
chromosomal (1), intra-chromosoma or inter-chromosomal of 16p-16p
and 21q-21q families (1/2), inter-chromosomal telomeric fusion events
(2T), inter-chromosomal fusions with the ancestral telomere at 2q13
(2A) and inter-chromosomal fusions with genomic loci (2G). Mean,
SD and SE are indicated below
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(Fig. 2e; Supplementary Table 11). Inter-chromosomal
fusions with non-telomeric loci (mean= 9.1 bp; n= 43),
together with intra-chromosomal sister-chromatid events
(mean= 4.1 bp; n= 32), displayed the greatest amounts of
junction microhomology. In contrast, very low or an
absence of microhomology at the fusion point was observed
for inter-chromosomal telomeric fusions (mean= 1.5 bp;
n= 315), Telomere-Telomere (TTAGGG-CCCTAA;
mean= 0.8 bp; n= 12) and Telomere-Sub-telomere
(mean= 1.6 bp; n= 303) subgroups. Long tracts of
microhomology of up to 23 bp, were observed at inter-
chromosomal fusion junctions with non-telomeric loci
(Fig. 2e). When the usage of microhomology was >10 bp,
the sequence was enriched for the repeat unit of (AC)n
(Supplementary Figure 5); 40% (6/15) of events that con-
tained at least (AC)5 (motif ACACACACAC), consistent
with repair utilizing single-stranded annealing [11].
Taken together, our data reveal the impact of short-
dysfunctional telomeres on the evolving CLL genome,
generating tumour heterogeneity that may affect patient
prognosis. We have revealed that dysfunctional telomeres
predominantly fuse with protein-coding DNA including
genes expressed in CLL B-cells and other tumours. We
have also identified complex telomere fusions involving
multiple non-telomeric loci across the CLL genome,
including those with known copy number aberrations in
CLL. Our data implicate diverse DNA repair mechanisms at
play in CLL tumour initiation and progression, including
C-NHEJ, A-NHEJ and SSA. These repair pathways provide
potential therapeutic targets and combinations of ther-
apeutic agents targeting these specific pathway components
may effectively sensitise CLL B-cell clones with ongoing
telomere dysfunction to improve patient outcomes.
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To the Editor:
Disruption of the intrinsic apoptotic pathway by the aberrant
expression of the BCL2 family members are frequent events in
multiple myeloma (MM). In particular, the anti-apoptotic pro-
tein myeloid cell leukemia-1 (MCL1) is highly expressed in
MM and plays a crucial role in disease progression [1, 2].
Using an unbiased approach to analyze cell death clustering,
Gomez-Bougie and colleagues recently identified a group of
MM patients insensitive to all the three classes of BH3
mimetics targeting MCL1, BCL2, and BCLxL. These BH3
mimetic-resistant patients were mostly found at diagnosis, and
they often do not possess any recurrent chromosomal translo-
cations. BCL2 dependency is mainly found in patients with t
(11;14) CCND1 translocation. BCLxL dependency is rare in
MM as they are often co-dependent on either BCL2 or MCL1.
MCL1 dependency was strikingly predominant at relapse and
in patients lacking common translocations and in the
CCND1 subgroup. These findings suggested a shift of cellular
plasticity towards MCL1 dependence during disease progres-
sion as a result of prior treatments or clonal selection [3].
A majority of well-established human MM cell lines and
low-passage patient-derived myeloma cell lines have been
shown to be MCL1 dependent using pharmacological
inhibitors or gene editing approaches that specifically target
MCL1 [4]. Clinically, overexpression of MCL1 is observed
in 52% of MM patients at diagnosis and 81% at relapse. The
level of MCL1 expression correlates with disease progres-
sion, and a higher MCL1 expression is associated with
shorter survival [5]. Since MM is heavily reliant on MCL1,
MM patients, particularly those at relapse, would benefit
from an MCL1-targeted therapy. However, there is no
FDA-approved drug with the ability to selectively target
MCL1. To address this unmet medical need, a few selective
MCL1 inhibitors are currently being developed in pre-
clinical phase or clinical trials and have thus far shown
promising results as single agents or used in combination
with established therapies in various cancers, particularly in
hematologic malignancies [6–8]. To further explore MCL1
biology in MM, we use a clinical-grade small-molecule
MCL1 inhibitor, AZD5991, to investigate the mechanistic
underpinning of MCL1 inhibition in MM.
AZD5991 is a potent and selective macrocyclic inhibitor of
MCL1 [9] that is currently in phase I clinical trial in patients
with relapsed or refractory MM and other hematologic
malignancies (ClinicalTrials.gov Identifier: NCT03218683).
Using AZD5991 as a test compound, we aimed to determine
the survival dependency of human MM cells on the anti-
apoptotic protein MCL1. First, we evaluated the cytotoxicity
of AZD5991 on a panel of MM cell lines. MM cell lines
showed a heterogeneous response to MCL1 inhibition.
AZD5991 treatment resulted in dose-dependent cytotoxicity
with EC50 values (Table S1) ranging from 64 nM to 417 nM at
24 h for AZD5991-sensitive cell lines (Fig. 1a). We next
assessed the effect of AZD5991 in MM patient-derived
CD138+ cells. AZD5991 treatment led to 40–82% decrease in
viability of primary cells isolated from relapsed and refractory
MM patients at a dose of 300 nM at 24 h (Fig. 1b). AZD5991
also induces potent anti-MM activity in vivo [9]. Together,
these results indicate that AZD5991 has promising single-
agent activity, but it would be prudent to study it in combi-
nation with other anti-MM therapies.
To understand the mechanism of cytotoxicity, we treated
the AZD5991-sensitive MM.1S and H929 cells with 50 nM
of AZD5991 for 24 h. The decrease in cell viability upon
MCL1 inhibition is due to an increase in apoptosis as shown
by an increase in Annexin V signals after MCL1 inhibition.
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On the other hand, the AZD5991-resistant DOX40 cells
showed no increase in Annexin V signals at the low dose
(Fig. S1). We next confirmed that the induction of apoptosis
in the AZD5991-sensitive cells is caspase-dependent and it
is induced primarily via the intrinsic apoptotic pathways as
shown by an increase in caspase-3 and caspase-9 signals
after AZD5991 treatment. The caspase signals were com-
pletely reversed with the addition of caspase inhibitors
(Fig. S2).
Since the bone marrow (BM) microenvironment enhan-
ces tumor cell growth and survival in MM, we next assessed
the effect of AZD5991 on the MCL1-sensitive MM.1S and
H929 cells in the presence of BMSC-conditioned media and
co-culture with bone marrow stromal cells (BMSCs). We
found that soluble factors produced during the MM-BMSC
interaction reduced the sensitivity of MM cells to
AZD5991, and direct MM-BMSC contact blunted the









































































































































































Fig. 1 The BM microenvironment confers a protective effect on MM
cells against MCL1 inhibition. a A panel of human MM cell lines was
treated with increasing doses of AZD5991 (0–1000 nM) for 24 h, and
cell viability was measured by CellTiter-Glo® One Solution Assay. b
Patient-derived CD138+ MM cells were treated with increasing doses
of AZD5991 for 24 h, and cell viability was measured as in a. All the
samples were derived from relapsed or refractory MM patients. c, d
MM.1S cells were cultured with increasing doses of AZD5991 for 24 h
in the presence of (c) BMSC-conditioned media or (d) BMSCs. Cell
viability in c was assessed by CellTiter-Glo® One Solution Assay. Cell
proliferation in d was evaluated by CyQUANT® NF Cell Proliferation
Assay. e Semi-quantitative detection of a panel of 80 human proteins
in cell culture media of MM.1 S cells, BMSCs, and BMSC+MM.1S
co-culture. Shown here are the top ten most highly-expressed cyto-
kines in the culture media. Signal intensity was normalized to uncul-
tured media
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protective effect of the BM microenvironment is mediated
via cytokines, as well as through MM-BMSC contact [10].
Importantly, MCL1 is the only anti-apoptotic protein within
the BCL2 family members whose expression is controlled
by cytokine treatment of MM cells [11, 12]. Therefore, we
carried out a comprehensive analysis of 80 human proteins
in cell culture media. Our cytokine array analysis revealed
an enrichment of a panel of pro-survival cytokines and
growth factors, with the cytokine IL-6 being among the
most highly up-regulated proteins, upon cell–cell contact
between MM.1S cells and BMSCs (Fig. 1e and Fig. S4). IL-
6 is known to enhance MCL1 expression via STAT3
signaling in MM [11, 13], making the cells more MCL1
dependent. The fact that a higher concentration of
AZD5991 could overcome the soluble resistant factors in
the BM milieu implied cytokines and growth factors only
contribute partially to MCL1 resistance. Direct cell–cell
contact in the BM microenvironment protects MM cells
from AZD5991-induced cell death. The co-culture with
BMSCs increased MCL1, BCLxL, and Bim expression in
MM.1S cells (Fig. S5), further enhancing their co-
dependence on MCL1 and BCLxL for survival.
A shift in the balance of BCL2 family members is often the
primary reason for drug resistance [14, 15]. Although MM
cells mostly depend on MCL1 for survival, we hypothesized
that MM cells could switch their survival dependency to other
Fig. 2 AZD5991 in combination with Venetoclax induces synergistic
anti-MM activity and overcomes MCL1 resistance in MM. MM.1S
cells were either cultured alone (a) or co-cultured with BMSCs (b) and
treated with EC50 doses of AZD5991, Venetoclax (Table S1-S2), or in
combination for 6 h. Protein lysates were prepared from MM.1S cells
and subjected to co-immunoprecipitation with MCL1, BCL2, or
BCLxL antibodies. The pull-down protein complexes were subjected
to Western blot analysis to examine Bim binding to MCL1, BCL2, and
BCLxL, respectively. Total protein lysates were subjected to Western
blot analysis to determine the amount of protein input for each treat-
ment. Densitometric analysis of Bim binding was performed using the
ImageJ software, and the percentage of Bim bound to MCL1, BCL2,
and BCLxL under different treatment conditions were presented in the
stacked bar graphs. c MM.1S cells were treated with increasing doses
of AZD5991 and Venetoclax for 24 h. Cell viability was assessed by
CellTiter-Glo® One Solution Assay. The isobologram analysis con-
firms synergism. d The synergistic effect of the AZD5991/Venetoclax
combination was examined on GFP-expressing MM.1S in the BMSC
co-culture setting over 72 h. Cell viability of MM.1S cells was
assessed by quantitative fluorescence imaging. The isobologram ana-
lysis confirms greater than additive effect. e The combinatorial effect
of the AZD5991/Venetoclax/Dexamethasone regimen was examined
on GFP-expressing MM.1 S cells in the BMSC co-culture setting over
72 h. Cell viability of MM.1S cells was assessed by quantitative
fluorescence imaging
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anti-apoptotic proteins upon stress. For example, when
AZD5991 displaces Bim from MCL1, the excess Bim may be
sequestered by BCL2 or BCLxL, thereby allowing MM cells
to evade cell death. To test this hypothesis, we examined the
impact of MCL1 and BCL2 inhibition on the binding pattern
of Bim to anti-apoptotic proteins in MM. MM.1S cells and
patient-derived CD138+ cells were either cultured alone or in
co-culture with BMSCs and treated with AZD5991 or Vene-
toclax (a BH3 mimetic that selectively binds and inhibits
BCL2 [16]) alone or in combination. The protein lysates
prepared from the MM cells were then co-immunoprecipitated
with antibodies against MCL1, BCL2, and BCLxL to deter-
mine the relative levels of Bim bound to each anti-apoptotic
protein under each drug treatment condition. We found that
MCL1 inhibition by AZD5991 leads to release of Bim from
MCL1, but increased Bim binding to BCL2 and BCLxL.
BCL2 inhibition by Venetoclax releases Bim from BCL2 but
results in increased Bim binding to MCL1. Cotreatment with
AZD5991 and Venetoclax decreases the overall Bim bound to
the anti-apoptotic proteins (Fig. 2a, b and Fig. S6). These
results suggest that MM cells switch their survival dependency
to other anti-apoptotic proteins upon MCL1 inhibition and
simultaneous inhibition of both MCL1 and BCL2 could be an
effective way to overcome MCL1 resistance in MM.
Based on these observations, we combined AZD5991 with
Venetoclax for the treatment of MM. A significant decrease in
cell viability was observed with the combined therapy com-
pared with both drugs used alone (Fig. 2c and Fig. S7). Iso-
bologram analysis confirmed greater than additive or
synergistic effect upon co-treatment. The same in vitro
synergism was observed in AZD5991-resistant DOX40 cells
and Venetoclax-resistant ANBL6VR cells (Fig. S8). The
enhanced cytotoxic effect of the combined therapy was pre-
served even when the MM cells are in co-culture with BMSCs
(Fig. 2d and Fig. S9). No cytotoxic effect was observed when
patient-derived BMSCs were exposed to this combined ther-
apy (Fig. S10). Cotreatment with AZD5991 and Venetoclax
also enhanced primary MM cell death in patient-derived bone
marrow (Fig. S11), suggesting that this combination regimen
is effective in the BM milieu.
Although AZD5991 in combination with Venetoclax is
effective in inducing synergistic anti-MM activity, the
concentration of Venetoclax used in the initial testing was
relatively high. A recent report showed that dexamethasone
(Dex) enhances the expression of both BCL2 and Bim in
MM, and consequently shifts Bim binding towards BCL2
and promotes BCL2 dependence in MM [17]. Thus, Dex
sensitizes MM cells to Venetoclax. To achieve therapeutic
concentrations, we added low-dose Dex to the AZD5991/
Venetoclax regimen and found that addition of Dex sig-
nificantly augments the effect of MCL1 and BCL2 blockade
in MM. We were able to achieve the same cytotoxic effect
on MM cells in the BMSC coculture with a much lower
dosage of both AZD5991 and Venetoclax (Fig. 2e and
Fig. S12), which is critical for clinical translation.
We discovered a MCL1 resistance mechanism in MM that
is driven by Bim binding to other anti-apoptotic proteins upon
MCL1 inhibition. Our data demonstrated that the combined
AZD5991/Venetoclax therapy overcomes MCL1 resistance in
MM. Concomitant suppression of both MCL1 and BCL2
prevent MM cells from escaping apoptosis by releasing Bim
from the anti-apoptotic proteins to activate the intrinsic
apoptotic pathway. With the addition of Dex which enhances
BCL2 and Bim expression and promotes BCL2 dependence,
we can achieve therapeutic dosage for both AZD5991 and
Venetoclax in MM treatment. As a proof of concept, our data
indicate combining therapeutics that selectively target the
anti-apoptotic proteins MCL1 and BCL2 could be an effective
therapy for MM patients, particularly those who suffered from
relapsed or refractory disease.
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To the Editor:
Chimeric antigen receptor (CAR)-T cell treatment as an
emerging tumor immunotherapy has produced exciting results
in relapsed or refractory B cell acute lymphoblastic leukemia
(B-ALL) [1–4]. However, few data are available on the ther-
apeutic effect of CAR-T against central nervous system leu-
kemia (CNSL). Here, we evaluated the feasibility and safety of
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anti-CD19 CAR-T against CNSL after intrathecal che-
motherapy in three adults with relapsed or refractory B-ALL.
Patient 1 with isolated CNSL, was refractory to high dose
methotrexate plus vindesine and L-asparaginase, and intrathecal
chemotherapy, accompanied by bone marrow (BM) sustained
remission with minimal residual disease (MRD) negative.
Patient 2 initially experienced a CNS relapse, and underwent
intrathecal chemotherapy, systemic chemotherapy and radio-
therapy. However, her CNSL was not controlled, accompanied
by BM recurrence. Patient 3 received prophylactic intrathecal
chemotherapy after his first complete remission (CR) but
experienced a rapid recurrence in his BM and CNS. They were
enrolled in our anti-CD19 CAR-T clinical trial (ChiCTR-ONN-
16009862). Prior to CAR-T cell infusion, all the patients
received conditioning chemotherapy with fludarabine and
cyclophosphamide, and intrathecal chemotherapy to reduce
blasts in the cerebrospinal fluid (CSF). Detailed patient and
methodological information are described in Supplementary
Methods, Table S1, and Figure S1.
First, we assessed the clinical response of CNSL to CAR-T
therapy in these patients. All patients with CNSL achieved CR
approximately one to two weeks post CAR-T infusion
(Fig. 1a–c), accompanied by BM remission with MRD
negative in patient 2 and patient 3 (Fig. 1d). One month after
CR, patient 2 received allogeneic hematopoietic stem cell
transplantation. Until the most recent follow-up, her leukemia
free survival has been over 2 months. Interestingly, patient 1
and patient 3 receiving no further therapy for CNSL after
CAR-T infusion were in sustained remission for over
5 months (Table S1). A phase 1 dose-escalation trial reported
that two B-ALL patients with CNSL achieved CR after CAR-
T therapy [3]. Another clinical trial showed that two CNSL
patients at the time of CAR-T infusion subsequently had no
blasts in the CSF [2]. Dai and colleagues also reported that two
patients with active CNSL at the time of CAR-T infusion
Fig. 1 Clinical response, expansion and persistence of anti-
CD19chimeric antigen receptor (CAR)-T cells. a–c Cell counts of
CAR-T cells and tumor cells in the cerebrospinal fluid (CSF) before
and after CAR-T infusion. The black arrows indicate intrathecal
chemotherapy. dMalignant cells in the bone marrow (BM) of patient 2
and patient 3 pre and post-infusion. e The peak expansion levels of
CAR-T cells in the peripheral blood (PB), BM, and CSF
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became CNS negative [5]. Altogether, CAR-T can be a fea-
sible and effective treatment for CNSL.
We further evaluated the proliferation and persistence of
CAR-T in vivo. Two patients reached the peak expansion of
CAR-T cells in the CSF on day 8 (Fig. 1b, c), which
coincided with the disappearance of CSF blasts in the
responding patients. However, patient 1 exhibited peak
expansion on day 28, 2 weeks later than the disappearance
of the tumor cells in the CSF (Fig. 1a). The persistence time
of CAR-T cells in the CSF of patient 2 and patient 3 was
about 2–3 weeks (Fig. 1b, c), while in patient 1, 5.19% of
CAR-T cells persisted in the CSF on day 90 (Fig. 1a).
Patient 1 who only had CNS relapse, showed significantly
higher peak proportions of CAR-T cells in the CSF than
those in the peripheral blood (PB) and BM. However,
patient 2 and patient3 both with BM and CNS recurrence
exhibited markedly lower peak levels of CAR-T cells in the
CSF compared to patient 1 (Fig. 1e), but relatively high
peak levels in the PB and BM. These different distributions
of CAR-T cells may be explained by chemotaxis and sti-
mulated proliferation of effector cells at the tumor sites.
We next evaluated the adverse events associated with anti-
CD19 CAR-T treatment. Patient 1 only showed grade 1 ane-
mia and grade 4 lymphopenia on day 3 after infusion
(Table S2). She didn’t complain of any discomfort post CAR-
T therapy. It was reported that the severity of the cytokine
release syndrome (CRS) was correlated with tumor burdens
and T cell proliferation [2, 3, 6]. However, the peak expansion
time of patient 1 was two weeks later than the disappearance
of the tumor cells in the CSF (Fig. 1a), which may explain the
low risk of CRS. Patient 2 and patient 3 experienced grade 2
fever, grade 3 febrile neutropenia, grade 2 CRS, and grade 1
reduced consciousness. Patient 2 also had grade 1 cognitive
impairment and grade 2 convulsion. Dexamethasone was
administrated at 10mg q8h to control her seizure on day 8,
and was de-escalated on day 9 and discontinued on day 10.
These adverse events were well managed with supportive care
and dexamethasone. Other adverse events related to CAR-T
therapy are shown in Figure S2 and Table S2.
In summary, this study showed that anti-CD19 CAR-T
could effectively eliminated leukemia cells in the CNS with
fully reversible toxicity. We also found that patient with
only CNS recurrence had higher levels of CAR-T in the
CSF and relatively lower severity of toxic effects than
those with BM and CNS recurrence. This study shows that
anti-CD19 CAR-T might be a feasible and safe treatment
for CNSL after intrathecal chemotherapy in adults with B-
ALL, especially in isolated CNSL. More cases and further
studies are needed to verify these findings.
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To the Editor:
Diffuse large B-cell lymphoma (DLBCL) is the most
common type of non-Hodgkin lymphoma (NHL). In the
United States and United Kingdom, the annual prevalence
of DLBCL is as high as 0.08% [1]. The first-line clinical
treatment for DLBCL is combined chemo-immunotherapy
with a 5-year survival rate of around 58% for senior adults
[2]. Mantle cell lymphoma (MCL) contributes to more than
6–8% of NHL worldwide [3]. Because of the t(11;14)(q13;
q32) chromosomal translocation and upregulated expression
of cyclin D1, malignant proliferation is commonly observed
in MCL [4]. Unfortunately, there is no optimal therapy for
MCL [5] and the 5-year survival rate for MCL patients in
the United States is <50% [6]. These statistics highlight an
urgent need for the development of more effective treat-
ments for patients with DLBCL or MCL.
B-cell receptor (BCR) signaling is indispensable for the
adhesion, survival, and growth of B cells. As an essential
membrane proximal signal molecule in the BCR pathway,
Bruton’s tyrosine kinase (BTK) plays a critical role in B-
cell activation and proliferation [7]. In 2013, the BTK
covalent inhibitor ibrutinib was approved by the Food and
Drug Administration for the treatment of MCL. Addition-
ally, activated B-cell-like (ABC)-DLBCL patients achieved
remission after treatment with ibrutinib [8]. Unfortunately,
drug-resistant tumor cells have been isolated from MCL
patients during treatment with ibrutinib and the relapse-
specific C481S missense BTK mutation contributes to this
resistance [9]. In the growth inhibition of DLBCL, the BTK
C481S mutant also resulted in resistance to ibrutinib [10].
Proteolysis-targeting chimera (PROTAC) is a novel
strategy for selective knockdown of target proteins by
small molecules [11]. PROTAC molecules are hetero-
bifunctional compounds with three components: a target
protein-binding moiety, an E3 ligase ligand, and a linker
connecting the two (Fig. 1a). The degradation machinery
brings the target cellular protein to the corresponding E3
ligase, resulting in degradation by the ubiquitin-
proteasome system. In recent years, this newly devel-
oped method has been widely used in antitumor studies
[12, 13]. Recently, we developed the first PROTAC-
derived degrader for selective BTK degradation [10, 14,
15]. Although preliminary data showed that our degrader
effectively controlled BTK C481S mutant-induced ibru-
tinib-resistant B-cell malignancies in vitro, the following
critical questions remain unaddressed. (1) Is the BTK
degrader also effective for DLBCL in vivo? Due to the
poor aqueous solubility of the first generation of our
degrader, a new generation of BTK degraders with
improved solubility must be developed for in vivo
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evaluation. (2) Can our PROTAC molecules degrade
clinically relevant BTK mutants other than the C481S
mutant? (3) Does our degrader work well for treatment of
MCL? (4) Can our degrader achieve synergistic effects
with other inhibitors for ibrutinib-resistant B-cell
malignancies?
Here we reported the development of a next-generation
BTK degrader, L18I, based on the lenalidomide ligand
for cereblon. L18I exhibited good solubility in
phosphate-buffered saline. Remarkably, L18I induced
degradation of ibrutinib-resistant C481S BTK at a
working concentration as low as 30 nM in a human ABC-
DLBCL cell line, HBL-1, with exogenous overexpression
of the BTK C481S mutant. Moreover, L18I achieved
much lower half maximal growth-inhibitory concentra-
tion (GI50) values than ibrutinib in inhibiting the growth
of both DLBCL and MCL cells in vitro. As a further test,
L18I effectively degraded different C481 mutated BTK
proteins that were observed in clinically relevant B-cell
tumors. More importantly, in vivo experiments showed
that L18I induced rapid tumor regression of C481S BTK
HBL-1 xenograft tumors with no signs of toxicity in
mice. Lastly, combined with SYK, PI3K, or lyn inhibitor,
L18I achieved even higher inhibitory activity against
C481S BTK HBL-1 cells.
To develop an ideal degrader with improved aqueous
solubility for both in vitro and in vivo evaluations, we
optimized both ligand and linker (Fig. 1). After many
attempts, a suitable degrader, L18I, with ibrutinib and
lenalidomide ligands connected by a polyethylene gly-
col (PEG) linker was identified. The schematic diagram of
BTK degrader design was shown in Fig. 1f. This break-
through provided an opportunity to carry out
pharmacological experiments in vitro and in vivo (Supple-
mentary Table 1).
L18I efficiently degraded C481S BTK in HBL-1 cells,
and the half maximal degradative concentration (DC50) was
29 nM (Fig. 1b and Supplementary Fig. S1). PROTAC-
mediated degradation of C481S BTK occurred rapidly and
specifically. The half-life of C481S BTK in DLBCL cells
was <2 h in the presence of L18I (Fig. 1b and Supple-
mentary Figs. S2 and S3). As competitive inhibitors, ibru-
tinib and pomalidomide effectively blocked L18I-mediated
degradation of C481S BTK. NEDD8-activating enzyme
inhibitor MLN4924 or proteasome inhibitor bortezomib
also effectively prevented the degradation (Fig. 1a and
Supplementary Fig. S4).
Besides the C481S mutation, we investigated other
mutations at the 481 position of the BTK protein. C481T is
catalytically active ibrutinib-resistant BTK mutant, and the
C481G mutant has very weak catalytic activity [16], while
the C481A point mutation results in no covalent binding to
ibrutinib probe [17]. Therefore, new treatments to tackle
these potential drug-resistant mutants are urgently needed.
To confirm the degradation activity of L18I for different
BTK single-point mutants at the 481 position, six plasmids
expressing BTK C481 mutants were constructed. Except for
alanine and tryptophan mutations, all BTK single-point
mutants retained catalytic function (Fig. 1c). L18I effi-
ciently degraded all BTK single-point mutants, and the half
maximal effective concentrations were around 30 nM
(Fig. 1d, e).
Next, to evaluate the antitumor effect of L18I in vitro,
the C481S BTK HBL-1 cell line was tested. L18I effec-
tively inhibited the growth of mutant HBL-1 cells with a
GI50 of 64 nM. By contrast, the GI50 of ibrutinib was
2526 nM due to drug resistance (Fig. 2a). To study the
detailed effects of L18I in C481S BTK HBL-1 cells, we
examined the activities of downstream BCR signaling
molecules upon BTK degradation. In remarkable contrast
to ibrutinib, L18I potently inhibited the phosphorylation
of PLCγ-2, ERK1/2, and p38 (Fig. 1g and Supplementary
Fig. S8). We also assessed the in vitro antitumor efficacy
of L18I in MCL cells (Mino cells and Z138 cells) with
exogenous expression of the BTK C481S mutant. As
expected, L18I efficiently halted cell proliferation at
much lower concentrations than ibrutinib in C481S BTK
MCL cells. GI50s of L18I were all bellow 10 nM, almost
300-fold lower than those of ibrutinib (Fig. 2b). These
results illustrated that ibrutinib was unable to inhibit the
C481S BTK mutant in vitro, while the newly developed
degrader L18I showed excellent inhibitory effects in both
DLBCL and MCL BTK C481 mutant-expressing tumor
cells.
Based on these potent in vitro efficacies, L18I was fur-
ther examined in a mouse xenograft model inoculated with
Fig. 1 Schematic diagram and characterization of L18I, which
degrades the ibrutinib-resistant BTK C481 mutant. a Mechanism of
the newly developed BTK C481 mutant degrader. b Western blotting
analysis for C481S BTK and β-actin proteins after 36 h of treatment of
C481S BTK HBL-1 cells with indicated concentrations of L18I (left
panel). Western blotting analysis for C481S BTK and β-actin proteins
after treatment of C481S BTK HBL-1 cells with 100 nM L18I for the
indicated exposures (right panel). c Codons for amino acids in six
different C481 mutated BTK proteins. Catalytic function and degra-
dation of C481 mutated BTK proteins were indicated. d Plasmids
expressing full-length constructs of C481T (C/S) BTK were trans-
fected into HeLa cells using Lipo2000. These C481 mutated BTK
proteins have stronger catalytic function. Western blotting analysis for
C481T (C/S) BTK and β-actin proteins after 4 days of treatment of
HeLa cells with the indicated concentrations of L18I. e Plasmids
expressing full-length constructs of C481G (W/A) BTK were trans-
fected into HeLa cells using Lipo2000. Western blotting analysis for
C481G (W/A) BTK and β-actin proteins after 4 days of treatment of
HeLa cells with the indicated concentrations of L18I. f Schematic
diagram of BTK degrader design. g Western blotting analysis for p-
PLCγ-2, PLCγ-2, p-ERK1/2, ERK1/2, p-p38, p38, and β-actin pro-




C481S BTK HBL-1 cells. Rapid tumor regression was
achieved with 30 or 100 mg/kg of L18I administered
intraperitoneally every day for 2 weeks. Ibrutinib (30 and
100 mg/kg) was used as a negative control. Compared with
the vehicle group, tumor size of the 30 mg/kg L18I-treated
group was reduced by 36% (p= 0.0126). In the 100 mg/kg
L18I-treated group, tumor size was reduced by 63% (p=
0.0004). By contrast, in the ibrutinib treatment groups,
almost no reduction in tumor size was observed at low or
high doses (Fig. 2c). Relative C481S BTK protein levels in
fresh ex vivo tumor cells were also tested by immunoblot-
ting and immunohistochemistry. C481S BTK levels in
isolated tumors from L18I-treated mice were significantly
lower than those in the vehicle group (Fig. 2d, e). From the
safety evaluation, it was clear that mice treated with ibru-
tinib suffered from more severe body weight loss than mice
treated with L18I. To further confirm the safety of L18I,
acute toxicity experiments were conducted in the B6 mouse
model. All mice in the L18I-treated groups (250 and 300
mg/kg) were in good health during the 3 weeks after treat-
ment (Fig. 2f). Therefore, the newly developed BTK C481
mutant degrader L18I was well-tolerated and had a highly
efficacious antitumor effect in this mouse xenograft model.
Drug combination strategies with small-molecule
inhibitors are commonly used to treat refractory cancers.
In the current study, we for the first time tested the pos-
sibility of a drug combination therapy strategy with both
BTK degrader and BCR signaling molecule inhibitors.
The inhibitory effect against ibrutinib-resistant cell lines
was tested using several different targets. For instance,
GS-9973, a SYK inhibitor, has been used in potential
overcoming ibrutinib-resistant clones [18]. PI3K upregu-
lation has been documented in MCL with ibrutinib
resistance [9]. In addition, ibrutinib-resistant cells retain
sensitivity to lyn inhibitors, such as dasatinib [19]. Thus,
it is of interest to examine the synergistic effect of L18I
with SYK, PI3K, or lyn inhibitors. We performed these
experiments with C481S BTK HBL-1 cells. Remarkably,
in combination with GS-9973, L18I was more effective in
inhibiting C481S BTK HBL-1 cells, and the GI50 was as
low as 11 nM. Compared with the treatment using L18I
alone, a combination of L18I and a PI3K inhibitor,
copanlisib, dramatically improved the inhibitory effect on
C481S BTK HBL-1 cells, and the GI50 was lower than
5 nM. Additionally, a combination of L18I and dasatinib
effectively inhibited the growth of ibrutinib-resistant
HBL-1 cells with a GI50 under 5 nM (Fig. 2g and Sup-
plementary Fig. S9).
In summary, we present a newly designed C481 BTK
mutant-specific degrader L18I. With lenalidomide as the cer-
eblon E3 ubiquitin ligase ligand, the BTK degrader was
considerably more soluble. A series of clinically relevant BTK
mutants (C481S/T/G/W/A) were efficiently degraded by L18I.
Proliferation of BTK C481S mutant-expressing DLBCL and
MCL cells was potently inhibited in vitro by compound L18I,
whereas BTK covalent inhibitor ibrutinib exhibited very weak
efficacy. Meanwhile, downstream signaling activities were
strongly blocked by L18I, with effective concentration below
10 nM. More importantly, pharmacologic action of L18I
in vivo also resulted in an obvious antitumor effect in mouse
xenograft models inoculated with C481S BTK HBL-1 cells.
By contrast, ibrutinib had nearly no inhibitory activity in vivo,
which was consistent with the results from the in vitro
experiments. What’s more, compound L18I was found to be
safe and well-tolerated. Lastly, combined with GS-9973,
copanlisib, or dasatinib, L18I showed dramatically improved
efficacy in inhibiting ibrutinib-resistant cells, indicating
potential for combinations of inhibitor and degrader in the
treatment of drug-resistant cancers.
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Fig. 2 Pharmacodynamic and safety evaluation of L18I. a In vitro
study of growth inhibition effect on C481S BTK HBL-1 cells by L18I
and ibrutinib. In 96-well plates, 3000 cells were incubated in each well
at 37 °C for 72–96 h. The final GI50 was calculated using CCK-8. b In
vitro study of growth inhibition effect on MCL (Mino or Z138) BTK
C481S mutant overexpression cells by L18I and ibrutinib. In 96-well
plates, 3000 cells were incubated in each well at 37 °C for 72–96 h.
The final results were calculated using MTT. c L18I induced tumor
regression in the xenograft model of human C481S BTK HBL-1 tumor
cells with minimal body weight change compared with ibrutinib-
treated control. Tumor volume (means ± SEM) of vehicle-treated mice
(n= 7), mice treated with ibrutinib (30 mg/kg, n= 7; 100 mg/kg, n=
7), or mice treated with L18I (30 mg/kg, n= 7; 100 mg/kg, n= 7).
d Relative C481S BTK protein levels based on immunoblotting
of tumor lysates from mice treated with L18I (30 mg/kg, n= 7;
100 mg/kg, n= 7) and vehicle-treated mice (n= 7). e Immunohis-
tochemistry results of tumor biopsies from mice treated with L18I
(30 and 100 mg/kg) and vehicle-treated mice. Black bars represent
100 μM. White bars represent 20 μM. f In vivo acute toxicity experi-
ment results from mice treated with L18I (250 and 300 mg/kg).
g DLBCL drug combination therapies. In vitro study of growth inhi-
bition effect on C481S BTK HBL-1 cells by L18I combined with GS-
9973 or copanlisib. In 96-well plates, 3000 cells were incubated in
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To the Editor:
KRAS mutations are among the most common oncogenic
events in human carcinomas of endodermal origin, whose
presence predicts for resistance to several target therapies
[1]. Conversely, little is known regarding the role and/or
clinical impact of KRAS mutations in the setting of the
hematological malignancies, including chronic lymphocytic
leukemia (CLL), and only in recent years extensive
sequencing data have highlighted the recurrent mutations of
genes affecting the Ras–MAPK pathway in CLL [2, 3].
These mutations, by leading to a constitutive activation of
MAPK signaling pathway, have emerged as relevant in
driving impaired clinical responses to lenalidomide and
chlorambucil, and acquired resistance to fludarabine as well
as to PI3K and BCL2 inhibitors [4–6]. In this context, some
studies pinpointed a higher frequency of mutations in
members of the Ras–MAPK pathway in CLL cases with
specific clinico-biological features [6, 7], including the
presence of trisomy 12, a cytogenetic aberration associated
with a unique pathophysiology among CLL [8, 9], and/or an
unmutated (UM) configuration of IGHV genes, although a
dedicated and comprehensive analysis of these aspects is
still missing.
This study, approved by the IRB of the Aviano Centro di
Riferimento Oncologico (Approvals n. IRB-05-2010 and n.
IRB-05-2015), included 534 primary CLL from treatment-
naive patients. The cohort was purposely enriched in tris-
omy 12 CLL by including 110 cases from the Mayo Clinic,
Rochester, MN [8] to better evaluate the incidence of
mutations of the Ras–MAPK pathway in these subsets.
Overall, out of 534 cases, trisomy 12 CLL accounted for
300 cases (190 with trisomy 12 as the sole abnormality
[trisomy 12-only], and 110 with trisomy 12 plus another
abnormality on FISH [trisomy 12-plus]), 332 cases had UM
IGHV genes, and 214 cases had NOTCH1 aberrations
(details in Table S1). CLL patients were diagnosed and
treated according to the current iwCLL 2018 guidelines
[10], and all samples were collected at diagnosis from
treatment-naive patients. In 442/534 cases (clinical cohort),
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treatment-free survival (TFS) data were available along with
a comprehensive clinical and biological characterization
(Table S1 and Supplemental Methods). This cohort showed
the expected clinical behavior according to both the strati-
fication of the established cytogenetic categories and to the
canonical prognosticators by univariable and multivariable
analyses (Supplemental Figure S1 and Table S2). Mutation
testing for KRAS, NRAS, BRAF, TP53, NOTCH1, BIRC3,
and SF3B1 was performed on DNA from CD19+ enriched
CLL samples by Next Generation Sequencing (NGS) assays
with at least 1000 × coverage and 1% sensitivity (details in
Supplemental Methods). Groups were compared by chi-
square test; TFS was computed from diagnosis to treatment
and analyzed by log-rank test and Cox regression analysis
with a stepwise procedure using MedCalc Statistical Soft-
ware version 16.8.4 (MedCalc Software bvba, Ostend,
Belgium; https://www.medcalc.org; 2016).
The mutation analysis of the Ras–MAPK pathway was
focused on the KRAS, NRAS, and BRAF genes, previously
reported as the most frequently mutated genes among the
members of the pathway [2]. We found 91 missense point
mutations in 64 CLL cases, with a prevalence of KRAS
(44 mutations in 38 [7.1%] patients), followed by BRAF
(32 mutations in 24 [4.5%] patients) and NRAS (15 muta-
tions in 13 [2.4%] patients). Nearly all mutations were
previously associated with the gain-of-function phenotype
and increased RAS/ERK downstream signaling (Fig. 1a and
Table S3) [1]. In particular, among the most frequent KRAS/
NRAS mutations, almost half of the mutations (27/59, 45%),
overall affecting 23/49 (47%) patients, involved the G12/
G13 codons, in keeping with what was observed in colon
and lung cancers (Table S3) [1]. The co-occurrence of 2
mutated genes was observed in 11 cases (KRAS and BRAF
in 8/11 cases, KRAS and NRAS in 2/11 cases, NRAS and
BRAF in 1/11 cases), whereas mutations affecting all three
genes were not found in our cohort. The mutations were
mainly subclonal (mean Variant Allele Fraction, VAF,
12.3%, range 1.3–61.6%) with one-third of mutations (33/
91) above 10% VAF. The presence of multiple mutations
affecting the same gene occurred in 14 cases, including 5
cases that presented mutations in the same or adjacent
codons (i.e., one case with both K601N and K601E BRAF
mutations, one case with V600E and K601E BRAF muta-
tions, and three cases with two simultaneous KRAS muta-
tions at the G12 and G13 codons) suggesting that multiple
genetic hits are positively selected in different subclones
within the same leukemia specimen.
A strong association between KRAS/NRAS/BRAF muta-
tions and the presence of an UM IGHV gene status and
trisomy 12 was observed (Fig. 1b and Table S4). Overall,
87.3% of KRAS/NRAS/BRAF mutated cases had UM IGHV
(p < 0.0001) and 79.7% were trisomy 12 CLL (p < 0.0001).
Concordantly, the highest KRAS/NRAS/BRAF mutation
frequency was found in CLL patients with concomitant UM
IGHV and trisomy 12-only (38/133, 28.6%). This group
was characterized by 25 KRAS (18.8%), 8 NRAS (6%) and
11 BRAF (8.3%) mutated cases. Of note, the UM IGHV/
trisomy 12-only group was characterized by a higher fre-
quency of KRAS/NRAS/BRAF mutations also when com-
pared to the UM IGHV/trisomy 12-plus group (8/49,
16.3%). Finally, the lowest frequency of KRAS/NRAS/
BRAF mutations was observed in the context of CLL
patients with M IGHV (8/186, 4.3%) and del13q as the sole
chromosomal aberration (2/94, 2.1% in the whole cohort,
and 2/53, 3.8% in the context of UM IGHV cases).
We then correlated the presence of KRAS/NRAS/BRAF
mutations to other biological features (Table S4). When
considering the whole CLL cohort, the only variables
associated with a higher frequency of KRAS/NRAS/BRAF
mutations were the absence of BIRC3 mutations (p= 0.02)
and the positive expression (≥30%) of CD49d (p= 0.04).
On the other hand, if circumscribing the analysis to UM
IGHV/trisomy 12 CLL, CD49d positive expression lost its
association with KRAS/NRAS/BRAF mutations, as expected
due to the almost universal CD49d expression in trisomy
12 CLL patients [9]. Conversely, we observed a higher
frequency of KRAS/NRAS/BRAF mutations in NOTCH1
wild type cases (29/92, 31.5%) and BIRC3 wild type cases
(41/132, 31.1%) compared to their mutated counterparts
(NOTCH1 mutated: 17/90, 18.9%; BIRC3 mutated: 4/30,
13.3%; p= 0.05 in both cases), pointing to a mutual
exclusivity of these mutations in the pathogenesis of the
disease. No other significant associations with other known
prognostic variables such as presence of TP53 mutations/
disruption, SF3B1 mutations, ZAP-70 and CD38 expres-
sion, Rai staging, age at diagnosis, and gender were
observed either in the whole cohort or in the UM IGHV/
trisomy 12 cohort (Table S4).
We finally evaluated the prognostic relevance of
KRAS, NRAS, and BRAF mutations as predictors of TFS.
In the context of the clinical cohort, the presence of either
KRAS or NRAS mutations or the concomitant presence of
KRAS/NRAS mutations were associated with shorter TFS
(p= 0.07, p= 0.05, and p= 0.02, respectively) (Table 1,
Fig. 1c). Conversely, BRAF mutations were not asso-
ciated with TFS, pointing to a secondary role of BRAF in
the Ras–MAPK pathway in CLL, in line with studies
indicating the lack of therapeutic effects of BRAF inhi-
bition in CLL [11]. In a multivariable model that included
the main known CLL prognosticators, the presence of
KRAS/NRAS mutations retained its independent prog-
nostic power as predictor for shorter TFS (p= 0.03,
Table 1). Moreover, circumscribing the analysis to the
CLL subgroup with the highest incidence of these
mutations (i.e., UM IGHV/trisomy 12-only/NOTCH1-
wt), both KRAS mutations alone (p= 0.005) and KRAS/
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dwhole cohort UM IGHV/trisomy 12-only/NOTCH1-wt
Fig. 1 Type, incidence and prognostic impact of KRAS, NRAS and
BRAF mutations. a Lollipop plots of mutations found in KRAS, NRAS,
and BRAF genes. Sites and frequency of missense point mutations, and
schematic presentation of the protein structure and functional domains
are shown (MutationMapper, cBioPortal Version 1.14.0, Gao et al.
Sci. Signal. 2013 and Cerami et al. Cancer Discov. 2012). Gray boxes
indicate amino acids (aa) regions corresponding to the sequenced
amplicons. RBD, Ras-binding domain; C1_1, phorbol esters/dia-
cylglycerol binding domain (C1 domain); Pkinase_Tyr, protein
tyrosine kinase domain. b Co-mutation plot of 534 CLL analyzed for
KRAS, NRAS, BRAF mutations. Incidence of trisomy 12, KRAS, NRAS,
and BRAF missense mutations, NOTCH1 aberrations and IGHV status
are shown. c Kaplan–Meier curves of treatment-free survival (TFS) of
442 CLL patients stratified by the presence of KRAS and/or NRAS
mutations. d Kaplan–Meier curves of TFS of 61 CLL patients in the
IGHV unmutated/trisomy 12-only/NOTCH1-wt group stratified by the
presence of KRAS mutations
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NRAS mutations (p= 0.05) were associated with shorter
TFS (Fig. 1d and Table S5), and the presence of KRAS
mutations retained its prognostic value in a multivariable
analysis that included all the variables with an impact in
univariable analysis (p= 0.01, Table S5). The subclonal
or clonal pattern of KRAS/NRAS mutations had similar
negative impact in our series (not shown), as previously
observed for other gene mutations in CLL [12], and in
keeping with the known capability of KRAS mutated
tumor cells to enhance the overall tumor cell fitness by
influencing the non-mutated neoplastic component [13].
In the present study, we demonstrated that KRAS,
NRAS, and BRAF mutations were almost exclusively
found in UM IGHV/trisomy 12 CLL and were almost
mutually exclusive with NOTCH1 and BIRC3 mutations.
The type of genomic structural variants, especially tris-
omy 12 and del13q, strongly influenced KRAS/NRAS/
BRAF mutation incidence, that turned out to be at the
highest level in cases bearing trisomy 12 as the sole
genomic aberration, intermediate in cases in which tris-
omy 12 was associated with other genetic aberrations,
mainly del13q, and at the lowest level in cases bearing
del13q as the sole FISH detectable genetic aberration.
This peculiar distribution of KRAS/NRAS/BRAF mutation
incidence is in keeping with a CLL pathogenetic model in
which the two main founder genetic lesions (i.e., trisomy
12 and del13q) identify CLL subgroups following dif-
ferent patho-biological pathways. In particular, the pre-
sence of del13q, given its link to the miR15/miR16-
BCL2 axis, characterizes a CLL subset especially orien-
ted toward the amplification of anti-apoptotic signals
[14]. On the other hand, in trisomy 12 CLL, the co-
presence of KRAS/NRAS/BRAF mutations and/or
NOTCH1 mutations and/or BIRC3 mutations along with a
UM IGHV gene status and over-expression of surface
receptors mediating microenvironment interactions (e.g.,
CD49d) more likely characterizes CLL with amplified
pro-survival and proliferative signals [8, 9, 15]. This may
explain the clinical association between KRAS/NRAS
mutations and shorter TFS, as shown in the present
analysis.
Given the reported high risk of poor response and
development of chemo-resistance characterizing CLL cases
with KRAS/NRAS mutations [4–6], additional therapeutic
strategies should be considered for the treatment of these
cases, including MEK/ERK inhibitors, employed alone or
in combination with conventional therapies.
Acknowledgements The study was supported by the Fondazione
Umberto Veronesi, Post-doctoral Fellowships-year 2018 (to EV);
Associazione Italiana Ricerca Cancro (AIRC), Investigator Grant IG-
21687; Progetto Giovani Ricercatori no. GR-2011-02346826, no. GR-
2011-02347441, and no.GR-2011-02351370, Ministero della Salute,
Rome, Italy; Progetto Ricerca Finalizzata PE 2016-02362756, Minis-
tero della Salute, Rome, Italy; Associazione Italiana contro le Leuce-
mie, linfomi e mielomi (AIL), Venezia Section, Pramaggiore Group,
Italy; Linfo-check - Bando ricerca - contributo art. 15, comma 2, lett b)
LR 17/2014; “5x1000 Intramural Program”, Centro di Riferimento
Oncologico, Aviano, Italy; National Cancer Institute, CA197120 (to
TDS and NEK). Authors wish to thank Gustavo Baldassarre (Division
Table 1 Cox regression analysis
of treatment-free survival in the
whole cohort
Univariable Multivariable (n= 365)
N pts
analyzed
HR (95% CI) p-value HR (95% CI) p-value
male gender 442 0.97 (0.76–1.22) 0.8 − −
age ≥ 65 441 0.97 (0.77–1.23) 0.8 − −
Rai stage II–III–IV 434 2.60 (2.03–3.32) <0.0001 2.59 (1.98–3.41) <0.0001
CD49d positive (≥30%) 440 1.48 (1.13–1.92) 0.004 1.65 (1.22–2.23) 0.001
CD38 positive (≥30%) 439 1.13 (0.89–1.43) 0.3 − −
ZAP-70 positive (≥20%) 389 1.44 (1.11–1.87) 0.005 n.i. n.i.
IGHV unmutated 428 2.16 (1.66–2.8) <0.0001 1.83 (1.37–2.45) <0.0001
TP53 disrupted (del17p and/or
TP53 mutated)
442 1.70 (1.24–2.32) 0.0008 1.46 (1.05–2.03) 0.024
NOTCH1 mutated 442 1.37 (1.08–1.73) 0.009 n.i. n.i.
SF3B1 mutated 327 1.46 (0.90–2.38) 0.1 − −
BIRC3 mutated 343 0.93 (0.65–1.34) 0.7 − −
KRAS mutated 442 1.49 (0.96–2.30) 0.073 − −
NRAS mutated 442 1.86 (0.99–3.50) 0.055 − −
BRAF mutated 442 1.34 (0.75–2.40) 0.3 − −
KRAS/NRAS mutated 442 1.54 (1.05–2.25) 0.025 1.56 (1.04–2.36) 0.033
Factors with p-value <0.05 in univariable analysis were entered in the multivariable analysis
HR hazard ratio, CI confidence interval, n.i. variables not included in the model after stepwise selection
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To the Editor:
Up to 80% of CML patients using tyrosine kinase inhibitors
(TKIs) reports muscle complaints [1]. These muscle com-
plaints are strongly related to the presence of fatigue and
contributes to both diminished disease control [2] and
impaired quality of life [3]. Although the mechanism by
which TKIs cause muscle complaints is poorly understood,
mitochondrial dysfunction has been suggested to play a
pivotal role in TKI-induced cardiac muscle toxicity [4, 5].
We assessed whether TKIs disturb skeletal muscle mito-
chondrial density and function (cellular level), and if
this translates into alterations in muscle contractile function
(muscle tissue level) and maximal exercise
performance (whole-body level). To gain a better insight
into TKI-induced muscle complaints, these outcomes were
compared between CML patients with and without muscle
complaints. Written informed consent was obtained from
the participants prior to study enrollment. This study was
approved by the Local Committee on Research Involving
Human Subjects of the region Arnhem and Nijmegen,
the Netherlands and registered at The Netherlands Trial
Registry (NTR6373).
A total of twenty Ph+ CP-CML patients on TKI therapy
aged ≥ 18 were recruited from the Department of Hematol-
ogy at the Radboud University Medical Center (Nijmegen,
The Netherlands). CML patients were assigned to a group
with (CML+MC, N= 10) or without (CML -MC, N= 10)
muscle complaints (MC) on the basis of presence, onset and
course of muscle cramps, pain, and/or weakness. This was
quantified on a Likert scale from 1 (not at all) to 4
(very much) resulting in significant different scores between
CML+MC and CML -MC (median 4.0 (interquartile
range (IQR) 3.0–4.0) and 2.5 (IQR 2.0–3.0), respectively;
P= 0.002). The Brief Fatigue Inventory (BFI) [6] was used
to compare the degree of fatigue in CML patients, showing
higher fatigue levels in CML+MC when compared to
CML -MC (3.58 ± 2.19 and 0.95 ± 1.11, respectively; P=
0.005). Ten control participants were matched on group
level for age, gender, BMI and physical activity level,
assessed by The Short Questionnaire to Assess Health-
Enhancing Physical Activity (SQUASH) [7]. Subjects were
ineligible if they had hereditary muscle defects, diabetes
mellitus, hypo- or hyperthyroidism, severe electrolyte dis-
turbances, or used co-medication known to cause muscle
symptoms or have an effect on mitochondrial function
(e.g. statins, steroids, and metformin). Furthermore, subjects
These authors contributed equally: S. J. C. M. Frambach, N. A. E.
Allard and N. M. A. Blijlevens, S. Timmers
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with contra-indications for maximal exercise testing
according to the ACC/AHA guidelines [8] and muscle
biopsy (e.g. anticoagulant therapy, bleeding disorders) were
excluded. The demographic and hematological character-
istics shown in Table 1 are not statistically significant dif-
ferent between CML patients and controls and between
CML+MC and CML -MC, except for a higher Charlson
Comorbidity Index [9] score in CML patients when com-
pared to controls (median 2.0 (IQR 2.0–2.0) and 0.0 (IQR
0.0–0.0), respectively; P < 0.001) caused by the presence
of CML. All participants completed the study protocol,
i.e. a vastus lateralis muscle biopsy, electrical quadriceps
femoris stimulations, and an incremental cycling test.
Vastus lateralis muscle needle biopsies were performed
under local anesthesia in overnight fasted state and processed
for mitochondrial measurements according to standard lab
techniques as previously published [10]. Citrate synthase
activity, a marker for mitochondrial density, was not different
between CML patients and controls (195 ± 80mU/mg pro-
tein and 171 ± 30mU/mg protein, respectively, P= 0.24)
and between CML+MC and CML -MC (P= 0.33).
Furthermore, mitochondrial function, assessed by ATP pro-
duction capacity (Fig. 1a, c) and [1-14C]-pyruvate oxidation
rates in the presence of malate or carnitine (Fig. 1b, d) was
not different between groups.
Maximal voluntary muscle strength of the dominant
quadriceps femoris muscle [11], did neither differ between
CML patients and controls (8.3 ± 2.0N/kg and 7.9 ± 1.8 N/kg,
respectively; P= 0.59), nor between CML+MC and
CML-MC (P= 0.97). Resistance to fatigue was assessed by
electrically stimulating the quadriceps femoris muscle
repetitively at 40% of the MVC using 30 Hz bursts of one-
second duration every other second for two minutes [11].
This fatigue protocol resulted in a significantly larger force
decline in CML patients as compared to controls (31.8 ±
8.7% and 23.6 ± 7.7%, respectively; P= 0.010; Fig. 1e).
Although a similar fatigability pattern was observed
between CML+MC and CML -MC (force decline 29 ±
9% and 34 ± 9%, respectively; P= 0.24), the contractile
properties of the quadriceps femoris muscle during
repeated stimulation were explored in more detail. After
two minutes of stimulation CML+MC showed a
Table 1 Subject and hematological characteristics
Characteristics CML patients Controls P value CML+MC CML -MC P value
Subject number, N 20 10 – 10 10 –
Gender, male/female 14/6 7/3 1.00 7/3 7/3 1.00
Age, years 54 ± 8 58 ± 7 0.25 55 ± 9 54 ± 8 0.86
BMI, kg/m2 25.8 ± 4.1 27.5 ± 5.4 0.34 25.8 ± 3.6 25.8 ± 4.8 0.97
Physical activity, METmin/week; median (IQR) 2288 (1545–4982) 2850 (1965–4868) 0.53 2541 (1689–5488) 2070 (1403–4570) 0.63
Smoker, % 0 0 – 0 0 –
Age at Dx, years 46 ± 8 N/A – 47 ± 7 46 ± 9 0.78
BCR-ABL level, N (%) N/A – 1.00
No MMR 1 (5) 1 (10) 0 (0)
MMR or deeper 19 (95%) 9 (90) 10 (100)
TKI, N (%) – 0.89
Imatinib 10 (50) N/A 6 (60) 4 (40)
Dasatinib 5 (25) N/A 2 (20) 3 (30)
Nilotinib 2 (10) N/A 1 (10) 1 (10)
Bosutinib 2 (10) N/A 1 (10) 1 (10)
Ponatinib 1 (5) N/A 0 (0) 1 (10)
Duration of current TKI therapy, months; median (IQR) 42.5 (21.0–114.8) N/A – 66.5 (19.0–121.5) 38.0 (16.5–73.3) 0.63
Prior TKIs, N; median (IQR) 0.5 (0.0–1.0) N/A – 0.0 (0.0–1.0) 1.0 (0.0–1.0) 0.53
Charslon Comorbidity Index; median (IQR) 2.0 (2.0–2.0) 0.0 (0.0–0.0) <0.001 2.0 (2.0–2.0) 2.0 (2.0–2.0) 0.74
Potassium, mmol/l 3.9 ± 0.28 4.0 ± 0.20 0.50 3.9 ± 0.21 4.0 ± 0.34 0.76
Magnesium, mmol/l 0.82 ± 0.06 0.84 ± 0.06 0.49 0.82 ± 0.05 0.83 ± 0.06 0.63
Phosphate, mmol/l 0.82 ± 0.12 0.91 ± 0.17 0.11 0.83 ± 0.10 0.81 ± 0.15 0.75
Calcium, mmol/l 2.29 ± 0.09 2.30 ± 0.06 0.68 2.29 ± 0.09 2.29 ± 0.10 0.91
Albumin, g/l 38.7 ± 2.5 37.3 ± 2.0 0.13 39.1 ± 2.8 38.3 ± 2.2 0.48
TSH, mE/l; median (IQR) 2.1 (1.4–2.6) 2.0 (1.3–2.8) 0.90 2.0 (0.8–2.9) 2.1 (1.5–2.7) 0.61
CK, U/l; median (IQR) 137 (89–236) 120 (109–166) 0.61 169 (103–312) 127 (84–216) 0.90
Values are presented as mean ± SD unless indicated otherwise. There were no significant differences in subject and hematological characteristics
between CML patients, except for a higher Charslon Comorbidity Index score in CML patients Also, there were no significant differences between
CML patients with and without TKI induced muscle complaints
MC muscle complaints, BMI body mass index, MET metabolic equivalent of task, IQR interquartile range, Dx diagnosis, MMR major molecular
response, TKI tyrosine kinase inhibitor, TSH thyroid-stimulating hormone, CK creatine kinase
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Fig. 1 Skeletal muscle mitochondrial function and muscle function
parameters measured in CML patients and controls. a ATP production
rate normalized to muscle protein content and (b) [1-14C]-pyruvate
oxidation rates in the presence of malate and carnitine normalized to
muscle protein content measured in mitochondrial fractions from fresh
vastus lateralis muscle biopsies were not affected by TKI use. There
were also no differences in (c) ATP production rate and (d) [1-14C]-
pyruvate oxidation rates in the presence of malate and carnitine
between CML+MC and CML -MC. e Force decline expressed as
percentage of the prefatigue value during two minutes repetitive
electrical stimulation of the quadriceps femoris muscle shows a higher
level of muscle fatigue in CML patients compared to controls. Force
responses are plotted every second during the complete (120 sec)
fatigue protocol. f Maximal force rise after two minutes of electrical
quadriceps femoris stimulation was significantly lower in CML+MC
when compared to CML -MC. g Quadriceps femoris muscle in
CML+MC showed a tendency toward longer relaxation time
after two minute repetitive stimulation when compared to CML -MC.
h Reported fatigue by CML patients (assessed by the Brief Fatigue
Inventory) correlates with half relaxation time in quadriceps femoris
muscle after two minutes repetitive electrical stimulation (N= 15).
Data are presented as means ± SEM for a–d; and means ± SD for e–g.
*P value < 0.05 is considered statistically significant
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significantly lower maximal force rise (maximal slope
of force increment normalized for peak force) compared
to CML -MC (0.54 ± 0.10%/ms and 0.67 ± 0.13%/ms,
respectively; P= 0.038; Fig. 1f) and a tendency toward
longer half relaxation time (time taken for force to decline
from 50 to 25% of the peak force; P= 0.07; Fig. 1g). The
half relaxation time at the end of the fatigue protocol
strongly correlated with reported fatigue (rp= 0.72; P=
0.002; Fig. 1h). Since muscle relaxation is dependent upon
the activity of sarco/endoplasmic reticulum Ca2+-ATPase
(SERCA), an enzyme that mediates the re-uptake of cal-
cium into the sarcoplasmic reticulum (SR) of skeletal
muscle, SERCA activity was measured in whole-muscle
homogenates [11]. However, no significant differences in
SERCA activity were observed between CML+MC and
CML -MC (98.9 (IQR 79.3–110.7 mU/mg) and 101.5 (IQR
77.0–109.8 mU/mg), respectively; P= 0.97).
To measure whole-body fitness levels, all subjects per-
formed an incremental cycle ergometer test (Lode Excali-
bur; Groningen, the Netherlands) with continuous ECG
monitoring [10] to assess peak oxygen uptake (VO2peak).
VO2peak was 34.6 ± 8.4 ml/kg/min (100 ± 9% predicted) in
the CML patients, which was not different from the controls
(VO2peak 35.6 ± 7.5 ml/kg/min, 100 ± 9% predicted; P=
0.75). In addition, no differences in VO2peak were observed
between CML+MC and CML -MC (P= 0.38).
Collectively, CML patients on TKI therapy show no signs
of skeletal muscle mitochondrial dysfunction. However,
quadriceps femoris muscle of TKI users fatigues to a larger
extent upon repetitive stimulation when compared to con-
trols. Changes in muscle contractile properties are associated
with TKI-induced muscle complaints, as CML+MC show
a significant lower maximal force rise and a tendency toward
a delayed muscle relaxation after two minutes of electrical
quadriceps femoris stimulations. CML patients did not have
impaired maximal exercise performance.
On a cellular level, no effects of TKI therapy on skeletal
muscle mitochondrial density and function were found. These
results are in line with the only previous clinical case report in
which two CML patients, who had to interrupt or reduce
therapy with nilotinib because of muscle pain, failed to show
disturbances in mitochondrial oxidative enzyme reactions
[12]. Intriguingly, in vitro studies in C2C12 myotubes
showed no decline in ATP levels upon short-term imatinib
incubation of 30min [13], whereas long-term TKI-incubation
of 24 h showed decreased ATP levels overtime [5, 13].
Disturbances in heart mitochondrial function are sug-
gested to occur secondary to activation of a stress response
in the endoplasmic reticulum [4]. Perhaps, in skeletal
muscle, changes in the function of other cellular organelles
also precede mitochondrial disturbances. In support of this
hypothesis, CML patients on TKI therapy showed sig-
nificantly more muscle fatigue than controls, and CML+
MC showed delayed quadriceps femoris muscle force
generation and a trend toward delayed relaxation in fatigued
muscle compared to CML -MC. Since muscle fatigability,
force generation, and relaxation are largely dependent on
Ca2+ regelulation by the SR, changes in SR functioning
may underlie these findings [14]. In that respect, dis-
turbances in Ca2+ homeostasis [15], and SR abnormalities
(i.e., dilated SR with membrane whorls) [4] have been
found upon imatinib treatment in myocytes, but have never
been linked to muscle complaints. Although we found no
difference in SERCA activity between CML+MC and
CML -MC, muscle half relaxation time after 2-min stimu-
lation correlated positively with the perception of fatigue in
CML patients, and may therefore be an important key for
understanding the mechanism underlying fatigue in CML.
To the best of our knowledge, maximal exercise capacity
has not been assessed before in CML patients or other TKI-
users. Compared to controls, CML patients do not have
diminished maximal exercise capacity as measured by
VO2peak and have similar physical activity levels as controls.
VO2peak was also not different between CML+MC
and CML -MC, despite higher subjective fatigue levels in
CML+MC. These findings fit with the unaltered mito-
chondrial ATP production capacity, which is an important
determinant of VO22peak.
There are several limitations to this study. Due to the
exploratory character of the study a relatively large number of
measurements were performed in a small sample size.
Therefore, results should be cautiously interpreted. None-
theless, this design made it possible to examine the influence
of TKIs on multiple levels (i.e. cellular, muscle tissue and
whole body level) which offers broad insight into the effects
of TKIs in CML patients. Secondly, participants were only
included when they were able to perform all study measure-
ments. Thus patients who were unable to perform exercise
testing were excluded. Consequently, extreme cases of TKI-
induced skeletal muscle complaints were not included in this
study, which may have underestimated the results.
This study provides important information concerning
the effects of TKIs on skeletal muscle function and whole
body fitness and lays foundation for further studies to elu-
cidate the precise mechanism by which TKI therapy causes
muscle complaints and affects muscle function.
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To the Editor:
Multiple cooperating mutations are required to induce
transformation during the development of acute myeloid
leukemias (AMLs), and identification of these cooperating
mutations is essential for developing better combinatorial
AML therapies. SETBP1, which encodes an AT-hook
transcription factor [1, 2], likely plays a significant role in
driving human primary AML development as it was over-
expressed in up to 30% of primary AML patients [3, 4], and
its overexpression was capable of inducing AML develop-
ment in mice [5]. Consistent with its association with poor
patient prognosis [3, 4], SETBP1 overexpression also likely
plays an important role in the maintenance of leukemia-
initiating cells (LICs) as it was identified as a top compo-
nent of a LIC gene expression signature for human AMLs
[6]. SETBP1 may control the self-renewal of LICs through
direct transcription activation of oncogenes Hoxa9,
Hoxa10, and Myb, and repression of tumor suppressor gene
Runx1 [1, 5]. SETBP1 may also promote AML develop-
ment through its interaction and stabilization of oncoprotein
SET [3]. Despite the potentially significant contribution by
SETBP1 overexpression to the initiation and maintenance of
primary human AMLs, its cooperating oncogenic partners
in AML development remain unknown.
Using a mouse bone marrow transduction and trans-
plantation system, we showed previously that over-
expression of Setbp1 induced AML development in over
50% of the recipient mice in 10 months [5]. Such systems,
as shown by us and others, also could be used as a powerful
tool for identifying cooperating oncogenic mutations due to
insertional mutagenesis induced by retroviral vectors [7, 8].
Therefore, to identify potential cooperating mutations for
SETBP1 overexpression in AML development, we cloned
and sequenced a total of 26 retroviral integration sites from
16 Setbp1-induced mouse AMLs by splinkerette poly-
merase chain reaction (Supplementary Table 1). Integration
site sequences were subsequently matched against the
mouse genome sequence to identify their genomic loca-
tions. Interestingly, two leukemias carry independent
insertions at Mllt3 (Fig. 1a). Given that retroviruses inte-
grate in a largely random fashion into the genome, recurrent
integrations at Mllt3 strongly suggest that such integrations
may cooperate with Setbp1 in AML induction in these mice.
These two leukemias also expressed significantly higher
levels of Mllt3 mRNA than leukemias without such inte-
grations (Fig. 1b), further indicating that Mllt3 over-
expression potentially induced by the viral integrations was
likely responsible for cooperating with Setbp1 in leukemia
induction. The lack of Mllt3 overexpression in the rest of
the mouse leukemias examined suggests a non-essential role
for Mllt3 in Setbp1-induced leukemia development; how-
ever, significantly higher levels of MLLT3 expression were
detected in human AMLs with high-SETBP1 expression
than in samples with low-SETBP1 expression in an
expression profiling study of human AMLs (Fig. 1c) [9],
suggesting that this potential Setbp1/Mllt3 cooperation is
likely conserved and prevalent in human AMLs with
SETBP1 overexpression.
MLLT3, also known as AF9, first was identified as a
fusion partner for MLL1 in human myeloid leukemias [10].
Gene targeting in mice has revealed a critical role of Mllt3
in embryogenesis [11]. MLLT3 later was found to regulate
transcriptional elongation as a component of the super
elongation complex (SEC) [12]. This function of MLLT3 is
likely dependent on its ability to recognize H3K9
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acetylation [13]. A role forMLLT3 overexpression in cancer
development has not been reported previously.
To confirm cooperativity between Setbp1 and Mllt3 in
leukemic transformation, we cloned Mllt3 cDNA into the
pMSCV-PGK-Puro retroviral vector and examine the
effects of co-transduction with pMSCV-Mllt3-PGK-Puro
plus pMYs-Setbp1-IRES-GFP viruses on 5-fluorouracil
(5-FU)-treated bone marrow progenitors from C57BL/6
mice (Fig. 1d). We first compared the self-renewal potential





























































































Fig. 1 Mllt3 cooperates with Setbp1 to induce AML development.
a Schematic diagrams of genomic locations of retroviral insertions (red
triangles) at Mllt3 in two Setbp1-induced mouse leukemias BL6 and
BL20. b Real-time RT-PCR analysis of Mllt3 expression in indicated
Setbp1-induced leukemias relative to Rpl4 mRNA levels and control
healthy bone marrow cells (BM). c Relative expression levels (log2) of
MLLT3 in human normal bone marrow (BM), CD34+ cells, and AML
cells with and without SETBP1 overexpression (SETBP1 high and
low). Normalized expression data from microarray dataset published
by Valk et al. [9] was downloaded from Oncomine website
(http://www.oncomine.org/) and analyzed. d Schematic diagram
depicting mouse bone marrow transduction and subsequent serial
replating and transplantation assays for testing Setbp1/Mllt3 coopera-
tion in inducing leukemia transformation. e Mean and SD of relative
colony-forming potential of 5-fluorouracil (5-FU) treated bone marrow
(BM) progenitors transduced with pMYs-Setbp1-IRES-GFP (S),
pMSCV-Mllt3-PGK-Puro (M), or the combination (M+ S) in primary
(1st), secondary (2nd), and tertiary (3rd) platings on methylcellulose
in the presence of murine Scf (100 ng/ml), Il-6 (10 ng/ml), and Il-3
(6 ng/ml) (n= 3 for each transduction). The titer of Mllt3 and Setbp1
virus used for co-transduction was reduced by half compared to the
single-transduction groups to ensure same total viral titer being used
for each transduction group. Depending on the virus used, transduced
cells were purified by selection with puromycin at 48 h post-trans-
duction, by FACS based on GFP positivity at 72 h post-transduction,
or both before primary platings. Cells were re-plated every five days.
f Survival curves of irradiated B6-Ly5.2 mice receiving similarly
transduced cells as in E and also secondary recipient mice receiving
1 × 106 spleen cells from primary Mllt3+ Setbp1 leukemic mice
(2° Trans). ***P < 0.001; ****P < 0.0001 (two-tailed Student’s t test)
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or Mllt3 virus by serial replating assay on methylcellulose.
Cells singly transduced with Mllt3 virus failed to form
colonies after first plating, suggesting that Mllt3 over-
expression is not capable of inducing their self-renewal
in vitro (Fig. 1e). Both co-transduced cells and cells infected
with Setbp1 virus alone continued to form colonies of
myeloid progenitors on secondary and tertiary platings
(Fig. 1e), suggesting that the combined expression of
Setbp1 and Mllt3 like Setbp1 expression alone is capable of
immortalizing myeloid progenitors. Interestingly, con-
siderably increased colony formation by co-transduced cells
compared to cells singly transduced by Setbp1 virus was
observed at both secondary and tertiary plating (Fig. 1e),
further indicating that overexpression of Mllt3 may sig-
nificantly enhance Setbp1-induced self-renewal of myeloid
progenitors.
To test whether co-expression of Setbp1 and Mllt3 could
lead to accelerated leukemia development in vivo, we also
transplanted unpurified transduced cells into lethally irra-
diated B6-Ly5.2 mice. As expected from our previous stu-
dies, three of seven mice receiving cells singly transduced
by Setbp1 virus developed AML in 8 months (Fig. 1f). In
contrast, none of the recipient mice in Mllt3 transduction
group developed leukemia in the same period (Fig. 1f),
suggesting the overexpression of Mllt3 alone is not suffi-
cient to induce leukemia development. Importantly, 100%
of the recipient mice for the co-transduced cells developed
AML at a much reduced latency [76 ± 13 days (mean ± SD);
p < 0.0001, log-rank test] than mice of the Setbp1 group
(Fig. 1f). Resembling leukemic mice induced by Setbp1
alone, these mice developed similarly enlarged spleens and
displayed significant infiltrations of leukemic cells into
nonhematopoietic tissues including liver and lung (Sup-
plementary Table 2 and Supplementary Figure 1A).
Fluorescence-activated cell sorting analyses of the two
leukemia types showed similar percentages of green fluor-
escent protein-positive leukemia cells (83–95%) in the bone
marrow and spleen with a majority (75–85%) of the leu-
kemia cells in the bone marrow being positive for Gr-1 and
only a minority of the cells being weakly positive for CD19,
CD4, or Ter119 (Supplementary Figure 1B). However,
Mllt3+ Setbp1 AMLs have greatly increased number of c-
kit-positive cells (59 ± 2% vs. 3 ± 1%, mean ± SD) and less
Sca-1-positive cells (2 ± 1% vs. 10 ± 3%, mean ± SD) in
bone marrow than Setbp1 AMLs (Supplementary Fig-
ure 1B). Consistent with the c-kit expression pattern,
cytospin preparations of leukemic bone marrow and spleens
(Supplementary Figure 1C) revealed significantly higher
frequencies of myeloid blasts in Mllt3+ Setbp1 leukemic
mice than Setbp1 leukemic mice [70 ± 6% vs. 30 ± 8%
(mean ± SD) of all nucleated cells in the bone marrow].
Mllt3+ Setbp1 leukemias are also transplantable as sec-
ondary recipients receiving 1 × 106 spleen cells from
primary leukemic mice developed AML with a comparable
latency to recipients of Setbp1 leukemia cells (16 ± 2 days
vs. 17 ± 4 days, mean ± SD) (Supplementary Figure 2).
Moreover, to confirm that co-expression of Setbp1 and
Mllt3 in same cell is required for their cooperativity, both
proviruses were detected in genomic DNA from all ran-
domly selected colonies generated by these leukemic cells
(Supplementary Figure 3).
Hoxa9 activation is essential for Setbp1-induced trans-
formation [1]. It has been shown previously that Meis1
overexpression can cooperate with Hoxa9 activation to
induce AML development [14]. Therefore, we tested the
possibility that co-expression of Mllt3 with Setbp1 may
increase Meis1 expression in hematopoietic stem and pro-
genitor cells by transducing mouse lin−Sca-1+c-kit+ (LSK)
cells and analyzing their Meis1 expression at 72 h after
transduction and also in their primary, secondary, and ter-
tiary colonies. Mllt3 overexpression alone is not sufficient
to activateMeis1 as it failed to increaseMeis1 mRNA levels
at 72 h post-transduction (Supplementary Figure 4).
Although both overexpression of Setbp1 alone and together
with Mllt3 upregulated Meis1 mRNA to similar levels at
72 h (Supplementary Figure 4), significantly higher levels
of Meis1 mRNA and protein were detected in all serial
colonies overexpressing both Setbp1 and Mllt3 than in
colonies overexpressing Setbp1 only (Fig. 2a, b). Sig-
nificantly higher levels of Meis1 expression also were
detected in Mllt3+ Setbp1 AMLs than in Setbp1 AMLs
(Fig. 2c, d). Moreover, in supporting a critical role of
increased Meis1 expression in transformation induced by
Setbp1/Mllt3 cooperation, Meis1 deletion by Cre/ERT2 in
secondary colony cells produced from Meis1 conditional
LSK cells after Mllt3+ Setbp1 transduction significantly
decreased their colony-forming capability (Fig. 2e). These
results strongly suggest that a major cooperating mechanism
for Setbp1 and Mllt3 in leukemia induction may be their
cooperation in inducing high levels of Meis1 expression.
Interestingly, by performing chromatin immunoprecipita-
tion analysis on tertiary colony cells generated by LSK cells
co-expressing Setbp1 andMllt3, we also detected significant
Mllt3 binding at the Meis1 locus (Fig. 2f), further sug-
gesting that Meis1 is a direct transcriptional target of Mllt3.
This direct regulation of Meis1 transcription by Mllt3 is also
conserved in human AML cells as a significant positive
correlation between MLLT3 and MEIS1 expression was
observed in human AMLs expressing high levels of
SETBP1 (Supplementary Figure 5).
Overexpression of SETBP1 in primary AMLs has been
associated with poor disease prognosis, suggesting better
therapies are critically needed to improve treatment out-
come. Our study identifies MLLT3 as a common cooperat-
ing partner for SETBP1 in inducing human AML
development, indicating that inhibition of signaling
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Fig. 2 Meis1 is a direct transcriptional target of Mllt3. a Real-time RT-
PCR analysis of Meis1 expression in cells of primary (1st), secondary
(2nd), and tertiary (3rd) colonies formed by LSK cells transduced by
pMSCV-PGK-Puro+ pMYs-Setbp1-IRES-GFP (C+ S), or pMSCV-
Mllt3-PGK-Puro+ pMYs-Setbp1-IRES-GFP (M+ S) viruses. Relative
expression levels (mean ± SD) were calculated by normalizing to Rpl4
mRNA levels in the same sample and also to C+ S cells (n= 3 for
each transduction). GFP positive and puromycin resistant cells were
collected at 72 h post-transduction for the serial replating assay.
b Western blotting analyses of whole cell extracts prepared from the
same colony cells as in (a) using indicated antibodies. c Real-time RT-
PCR analysis of Meis1 expression in spleen cells of leukemic mice
induced by Mllt3+ Setbp1 co-transduction (M+ S) or Setbp1
transduction alone (S) and control mouse bone marrow cells (WT).
d Western blotting analyses of whole cell extracts prepared from the
same leukemia cells as in C using indicated antibodies. e Upper panel,
secondary colony cells generated by Mllt3+ Setbp1 co-transduced
LSK cells of indicated genotypes were examined by colony-forming
assay after treatment with 4-hydroxytamoxifen (4-OHT) or control
ethanol (EtOH) and their relative colony-forming potentials are shown
(mean ± SD, n= 3 for each transduction). Lower panel, different
Meis1 alleles including floxed (fl), knockout (ko), and wild-type (wt)
detected by PCR in the secondary colony cells after 4-OHT or EtOH
treatment. f Quantitative ChIP analysis of indicated genomic regions
relative to Meis1 transcriptional start site using a Mllt3-specific anti-
body or control IgG in tertiary colony cells generated by mouse
LSK cells similarly transduced as in (a). **P < 0.01; ***P < 0.001;
****P < 0.0001 (two-tailed Student’s t test)
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pathways downstream of MLLT3 may prove valuable for
treating such AMLs. MLLT3 activation in these AMLs is
likely independent of SETBP1 as no significant correlation
was detected between their expression levels and Setbp1
overexpression also failed to increase Mllt3 expression in
mouse LSK cells (Supplementary Figures 6 and 7). Coop-
erativity also may exist between MLLT3 and SETBP1
missense mutations in the development of other myeloid
neoplasms since SETBP1 missense mutants are known to
activate similar targets as wild-type SETBP1 [15]. As a
component of SEC, MLLT3 was shown to regulate tran-
scriptional elongation, but whether its overexpression could
play any role in cancer development was unclear. Our study
demonstrates for the first time that MLLT3 overexpression
can promote AML development by activating MEIS1 tran-
scription. Further studies using genomic and proteomic
approaches will be required to identify additional MLLT3
transcriptional targets promoting AML development and
also other transcriptional cofactors critical for such
activation.
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